

**CAVA HEALTHCARE INC.  
PRESS RELEASE**

**CAVA HEALTHCARE ANNOUNCES PUBLICATION OF THREE PRECLINICAL STUDIES ON THE EFFECT OF CURCUPHENOL COMPOUNDS IN INCREASING IMMUNE DESTRUCTION OF METASTATIC CANCERS**

Reversing Immune Evasion in Metastatic Cancers, Discovering Innovative Treatment Avenues

**Vancouver, British Columbia, December 12, 2023** – Cava Healthcare Inc. (Cava), a leading biopharmaceutical company, is delighted to announce the publication of three pivotal preclinical studies showcasing the remarkable efficacy of curcuphenol and its synthetic analogues in augmenting immune responses and mitigating tumour growth. Tailored to enhance the immune system's ability to eradicate metastatic cancers, these compounds address a critical need, as metastatic cancer constitutes approximately 90% of cancer-related fatalities.

- “Curcuphenols facilitate the immune driven attenuation of metastatic tumour growth”  
<https://www.frontiersin.org/articles/10.3389/fntpr.2023.1281061/full>
- “Curcuphenol possesses an unusual histone deacetylase enhancing activity that counters immune escape in metastatic tumours”  
<https://www.frontiersin.org/articles/10.3389/fphar.2023.1119620/full>
- “A novel cell-based screen identifies chemical entities that reverse the immune-escape phenotype of metastatic tumours”  
<https://www.frontiersin.org/articles/10.3389/fphar.2023.1119607/full>

Drawing from ethnobotanical studies that identify turmeric and cumin, specifically curcuminoids like curcuphenol, as potential cancer remedies, these findings mark a significant advancement. While the initial studies hinted at the potential benefits, further research was imperative to pinpoint the specific molecular entities responsible for distinct medicinal advantages. The groundbreaking studies, for the first time, elucidate how curcuphenol compounds elevate the immunogenicity of metastatic cancer cells, leading to their subsequent immune destruction and a reduction in tumour mass. The senior author of these studies is Dr. Wilfred Jefferies, Cava’s Chief Scientific Officer.

Adrian Wade, Cava’s Chief Operating Officer, remarked, “The restoration of immunosurveillance is a crucial step in empowering the body to identify and eliminate cancer cells. Cava has patents in multiple countries and jurisdictions for the applications of curcuphenols and related synthetic compounds for treating metastatic cancers. These studies provide the proof-of-concept for building new cancer treatment options using derivatives of natural compounds such as curcuphenol.”

Cava recently received notification of the patent's issuance pertaining to the use of curcuphenols for treating cancer and specific composition in matter claims in Canada. This announcement adds to the jurisdictions, including the European Patent Organization, Japan, and the U.S.A., where Cava has received notice that the patent cases have been granted. The issuance of this patent stands as a pivotal measure for Cava in safeguarding the commercial viability of drugs designed for the treatment of cancer.

For further information, please contact Adrian Wade at [news@cavahealthcare.ca](mailto:news@cavahealthcare.ca) or 604-370-1757.

### **On Behalf of the Board of Directors**

**Adrian Wade, Ph.D.**

COO and Director

Investor Relations and Corporate Communications

### ***CAVA IS FOCUSED ON ENHANCING OPTIMAL HEALTH BY PREDICTING, PREVENTING AND ALLEVIATING DISEASE***

Cava is a specialty biotechnology company focused on advancing drug development to address unmet medical needs in neurodegeneration, inflammation, and restoration of immune function. The Company has a patent protected portfolio of intellectual property and technology, concentrated on the development of a treatment for Alzheimer's Disease and various oncology related biomarkers and treatments.

### **Cautionary Note Regarding Forward-Looking Statements**

*This press release contains forward-looking statements and forward-looking information (collectively, "forward-looking statements") within the meaning of applicable Canadian and U.S. securities legislation, including the United States Private Securities Litigation Reform Act of 1995. All statements in this press release that are not purely historical are forward-looking statements and include statements regarding beliefs, plans, expectations, and orientations regarding the future including, without limitation, matters related to the Company's current and planned research and development programs, including in respect of the prosecution and maintenance of the patent portfolio, and the Company's prospect of success in executing its proposed plans. Often, but not always, forward-looking statements can be identified by words such as "will", "plans", "expects", "may", "intends", "anticipates", "believes", "proposes" or variations of such words including negative variations thereof and phrases that refer to certain actions, events or results that may, could, would, might or will occur or be taken or achieved. Forward-looking statements are based on certain assumptions regarding the Company, including, without limitation, expected growth, results of operations and research and development activities (including in respect of the patent portfolio), results of operations, performance, industry trends, growth opportunities, and that the Company will be able to obtain the financing required to carry*

*out its planned future business activities, retain and attract qualified research personnel and obtain and/or maintain the necessary intellectual property rights it needs to carry out its future business activities.*

*Actual results could differ from those projected in any forward-looking statements due to numerous factors including, risks and uncertainties relating to the actual results of research and development programs, the inability of the Company, to, among other things, protect its intellectual property, obtain any required governmental, regulatory or stock exchange approvals, permits, consents or authorizations required, commercialize any therapeutic and diagnostic technologies, execute its proposed business plans, pursue business partnerships, complete its research and development programs as planned, and obtain the financing required to carry out its planned future activities. Other factors such as general economic, market or business conditions or changes in laws, regulations and policies affecting the Company's industries may also adversely affect the future results or performance of the Company. These forward-looking statements are made as of the date of this press release and, unless required by applicable law, the Company assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in these forward-looking statements. Although the Company believes that the statements, beliefs, plans, expectations, intentions, and assumptions contained in this press release are reasonable, there can be no assurance that those statements, beliefs, plans, expectations intentions or assumptions will prove to be accurate. Readers should consider all of the information set forth herein and should also refer to other periodic reports provided by the Company from time-to-time. These reports and the Company's filings are available at [www.sedar.com](http://www.sedar.com).*

*Readers are cautioned that forward-looking statements are not guarantees of future performance or events and, accordingly, are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty of such statements.*